The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10700 malaria professionals are enjoying the free benefits of MalariaWorld today

in vitro

NOT Open Access | Plasmodium falciparum purine nucleoside phosphorylase as a model in the search for new inhibitors by high throughput screening

December 16, 2020 - 10:06 -- NOT Open Access
Author(s): 
Holanda RJ, Deves C, Pereira da Silva LH, et al.
Reference: 
Int J Biol Macromol. 2020 Dec 15;165(Pt B):1832-1841

Studies have shown that inhibition of Plasmodium falciparum Purine Nucleoside Phosphorylase (PfPNP) blocks the purine salvage pathway in vitro and in vivo. In this study, PfPNP was evaluated as a model in the search for new inhibitors using surface plasmon resonance (SPR). Its expression, purification, oligomeric state, kinetic constants, calorimetric parameters and kinetic mechanisms were obtained. PfPNP was immobilized on a CM5 sensor chip and sensorgrams were produced through binding the enzyme to the substrate MESG and interactions between molecules contained in 10 fractions of natural extracts.

NOT Open Access | Assessment of in vitro and in vivo antimalarial efficacy and GC-fingerprints of selected medicinal plant extracts

December 2, 2020 - 08:38 -- NOT Open Access
Author(s): 
Sachdeva C, Mohanakrishnan D, Kumar S, Kaushik NK
Reference: 
Exp Parasitol. 2020 Dec;219:108011

A hallmark of mortality and morbidity, malaria is affecting nearly half of the world's population. Emergence of drug-resistant strains of malarial parasite prompts identification and evaluation of medicinal plants and their constituents that may hold the key to a new and effective anti-malarial drug. In this context, nineteen methanolic extracts from seventeen medicinal plants were evaluated for anti-plasmodial potential against Plasmodium falciparum strain 3D7 (Chloroquine (CQ) sensitive) and INDO (CQ resistant) using fluorescence based SYBR-Green assay and for cytotoxic effects against mammalian cell lines.

NOT Open Access | A chimeric Plasmodium vivax Merozoite Surface Protein Antibody Recognises and Blocks Erythrocytic P. cynomolgi Berok Merozoites In Vitro

November 18, 2020 - 12:13 -- NOT Open Access
Author(s): 
Shen FH, Ong JJY, Sun YF, Lei Y, Chu RL, Kassegne K, Fu HT, Jin C, Han ET, Russell B, Han JH, Cheng Y
Reference: 
Infect Immun. 2020 Nov 16:IAI.00645-20

Research on erythrocytic Plasmodium vivax merozoite antigens is critical for identifying potential vaccine candidates in reducing vivax disease. However, many P. vivax studies are constrained by its inability to undergo long-term culture in vitro Conserved across all Plasmodium spp, merozoite surface proteins are essential for invasion into erythrocytes and highly expressed on erythrocytic merozoites, thus making it an ideal vaccine candidate.

Dimethyl fumarate reduces TNF and Plasmodium falciparum induced brain endothelium activation in vitro

October 22, 2020 - 15:42 -- Open Access
Author(s): 
Neida K. Mita-Mendoza, Ariel Magallon-Tejada, Priyanka Parmar, Raquel Furtado, Margaret Aldrich, Alex Saidi, Terrie Taylor, Joe Smith, Karl Seydel and Johanna P. Daily
Reference: 
Malaria Journal 2020 19:376, 21 October 2020

Cerebral malaria (CM) is associated with morbidity and mortality despite the use of potent anti-malarial agents. Brain endothelial cell activation and dysfunction from oxidative and inflammatory host responses and products released by Plasmodium falciparum-infected erythrocytes (IE), are likely the major contributors to the encephalopathy, seizures, and brain swelling that are associated with CM. The development of adjunctive therapy to reduce the pathological consequences of host response pathways could improve outcomes. A potentially protective role of the nuclear factor E2-related factor 2 (NRF2) pathway, which serves as a therapeutic target in brain microvascular diseases and central nervous system (CNS) inflammatory diseases such as multiple sclerosis was tested to protect endothelial cells in an in vitro culture system subjected to tumour necrosis factor (TNF) or infected red blood cell exposure. NRF2 is a transcription factor that mediates anti-oxidant and anti-inflammatory responses.

From Circulation to Cultivation: Plasmodium In Vivo versus In Vitro

September 23, 2020 - 09:06 -- Open Access
Author(s): 
Brown AC, Guler JL
Reference: 
Trends Parasitol. 2020 Sep 18:S1471-4922(20)30224-5

Research on Plasmodium parasites has driven breakthroughs in reducing malaria morbidity and mortality. Experimental analysis of in vivo/ex vivo versus in vitro samples serve unique roles in Plasmodium research. However, these distinctly different environments lead to discordant biology between parasites in host circulation and those under laboratory cultivation.

Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation

September 15, 2020 - 14:26 -- Open Access
Author(s): 
Gendrot M, Andreani J, Pradines B, et al.
Reference: 
Travel Med Infect Dis. 2020 Sep 8:101873

In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs.

Anti-SARS-CoV-2 Potential of Artemisinins In Vitro

September 15, 2020 - 10:05 -- Open Access
Author(s): 
Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, Zhang H, Yan Y, Zhao L, Li W, Zhang T, Xiao D, Guo X, Li Y, Yang J, Hu Z, Wang M, Zhong W
Reference: 
ACS Infect Dis. 2020 Sep 11;6(9):2524-2531

The discovery of novel drug candidates with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) potential is critical for the control of the global COVID-19 pandemic. Artemisinin, an old antimalarial drug derived from Chinese herbs, has saved millions of lives. Artemisinins are a cluster of artemisinin-related drugs developed for the treatment of malaria and have been reported to have multiple pharmacological activities, including anticancer, antiviral, and immune modulation.

Organoarsenic Compounds with In Vitro Activity against the Malaria Parasite Plasmodium falciparum

August 5, 2020 - 16:11 -- Open Access
Author(s): 
Basova S, Wilke N, Koch JC, Prokop A, Berkessel A, Pradel G, Ngwa CJ
Reference: 
Biomedicines. 2020 Aug 2;8(8):E260

The rapid development of parasite drug resistance as well as the lack of medications targeting both the asexual and the sexual blood stages of the malaria parasite necessitate the search for novel antimalarial compounds. Eleven organoarsenic compounds were synthesized and tested for their effect on the asexual blood stages and sexual transmission stages of the malaria parasite Plasmodium falciparum using in vitro assays.

NOT Open Access | In Vitro Antiprotozoal Effects of Nano-chitosan on Plasmodium falciparum, Giardia lamblia and Trichomonas vaginalis

July 16, 2020 - 07:42 -- NOT Open Access
Author(s): 
Elmi T, Rahimi Esboei B, Sadeghi F, Zamani Z, Didehdar M, Fakhar M, Chabra A, Hajialiani F, Namazi MJ, Tabatabaie F
Reference: 
Acta Parasitol. 2020 Jul 14

Treatment of parasitic infections with conventional drugs is associated with high toxicity, and undesirable side effects require cogent substitutions. Nanotechnology has provided novel approaches to synthesize nano-drugs to improve efficient antipathetic treatment.

NOT Open Access | Characterization of mitochondrial carrier proteins of malaria parasite Plasmodium falciparum based on in vitro translation and reconstitution

June 26, 2020 - 15:34 -- NOT Open Access
Author(s): 
Nozawa A, Ito D, Ibrahim M, Santos HJ, Tsuboi T, Tozawa Y
Reference: 
Parasitol Int. 2020 Jun 20:102160

Members of the mitochondrial carrier (MC) family of membrane transporters play important roles in cellular metabolism. We previously established an in vitro reconstitution system for membrane transporters based on wheat germ cell-free translation system. We have now applied this reconstitution system to the comparative analysis of MC proteins from the malaria parasite Plasmodium falciparum and Saccharomyces cerevisiae. We synthesized twelve putative P. falciparum MCs and determined the transport activities of four of these proteins including PF3D7_1037300 protein (ADP/ATP translocator), PF3D7_1004800 protein (ADP/ATP translocator), PF3D7_1,202,200 protein (phosphate carrier), and PF3D7_1241600 protein (S-adenosylmethionine transporter).

Pages

Subscribe to RSS - in vitro